Please assess the completion status of the following clinical trial:

Trial Title: The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed.~* Male or female subjects at least 12 years old and in good general health.~* Able to complete the study and to comply with study instructions.~* Moderate plaque-type psoriasis on the body (excluding the scalp and face) defined as:~  * Plaque-type psoriasis involving 3% to 10% of total body surface area (BSA).~ * An Investigator's Static Global Assessment (ISGA) score of 3 at Baseline.~ * Identification of a target lesion (\>2 cm²) on the trunk or extremities with a score of 2 or 3 (0-5 scale) for erythema, scaling and plaque thickness. Lesions on the palms/soles, knees, elbow, and intertriginous areas should not be used as the target lesion site.~* Involvement of at least 10% of the total scalp surface area with clinical signs (erythema, thickness, and scaliness) rated as moderate (3) based on the ISGA.~* Negative urine pregnancy test for females of childbearing potential. • Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are fewer than 2 years from their last menses.~Exclusion Criteria:~* Any subject who has participated in any previous calcipotriene foam clinical.~* Female who is pregnant, trying to become pregnant, or breastfeeding.~* Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations.~* History of hypercalcemia or of vitamin D toxicity.~* Other serious skin disorder or any chronic medical condition that is not well-controlled.~* Use of nonbiologic systemic anti-psoriatic therapy (eg, corticosteroids, psoralen combined with exposure to ultraviolet light A \[PUVA\], ultraviolet light B \[UVB\], retinoids, methotrexate, cyclosporine, other immunosuppressive agents) within 4 weeks prior to enrollment.~* Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives (whichever is longer) for experimental products prior to randomization.~* Use of topical therapies that have a known beneficial effect on psoriasis, including but not limited to corticosteroids, retinoids, Vitamin D derivatives, coal tar, or anthralin, within 2 weeks prior to enrollment.~* Systemic medications for other medical conditions that are known to affect psoriasis (eg, lithium, beta adrenergic blockers) within 4 weeks prior to enrollment.~* Use of any investigational product within 4 weeks prior to enrollment, currently participating in another clinical trial, or plans to receive an investigational product during the study.~* Current drug or alcohol abuse (drug screening not required).~* Has a history of any immuno-compromizing disease.~* Any other condition that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.~* Employees of the investigator; study center; or Stiefel, a GSK company involved in the study; or an immediate family member (eg, partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcipotriene Foam (Type: EXPERIMENTAL): Calcipotriene Foam 0.005%,
- Vehicle Foam (Type: PLACEBO_COMPARATOR): Vehicle Foam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete